7/109 sources · 4 publishersUpdated Nov 6, 23:39 UTC
Xeris Biopharma posts 44% revenue jump, raises 2026 guidance and 2030 billion‑dollar target
Xeris Biopharma reported third‑quarter 2026 revenue of about $107 million, a 44% year‑over‑year increase driven by a 93% surge in Recorlev sales. Net income rose to $11.3 million and adjusted EBITDA to $30.8 million. The company lifted its full‑year revenue outlook to $395 million‑$405 million and set a new goal of more than $1 billion in total revenue by 2030.
Why it matters
The higher revenue guidance expands the upside for investors, as the company now expects a larger top line for the year. The 2030 billion‑dollar target signals a long‑term growth trajectory that could support a higher valuation.
Key facts
- 1Quarterly revenue was $107 million, up 44% year‑over‑year. ibtimes.com.au
- 2Recorlev net revenue was $71.5 million, an increase of 93% year‑over‑year. ibtimes.com.au
- 3Net income for the quarter was $11.3 million. ibtimes.com.au
- 4Adjusted EBITDA reached $30.8 million, up 77% year‑over‑year. finance.yahoo.com
- 5Full‑year 2026 revenue guidance was raised to $395 million‑$405 million. finance.yahoo.com
- 6The company now targets more than $1 billion in total revenue by 2030. seekingalpha.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.